IDH2 and glioblastoma: Although this study suggests CRYAB as a possible indirect biomarker for IDH1-R132H mutation, further investigations are needed because the regulation difference could be caused by the grade difference between tumor samples, as IDH-wildtype anaplastic astrocytoma shares molecular features of the IDH-wildtype glioblastoma [1].